Anupam Rasayan Launches Open Offer for Bliss GVS Pharma Control

Anupam Rasayan India Limited will acquire up to 26.00% of Bliss GVS Pharma Limited's voting share capital for up to ₹829 crore.
The offer price is ₹299.00 per equity share, with the tendering period from July 16, 2026, to July 29, 2026.

Reader Takeaway: New promoter acquisition offers exit at premium; future strategy shifts key.

What just happened

Anupam Rasayan India Limited has entered into a Share Purchase Agreement (SPA) to acquire 43.30% of Bliss GVS Pharma Limited. This transaction triggers a mandatory open offer for an additional 26.00% of Bliss GVS Pharma's expanded voting share capital at ₹299 per share. Upon completion, Anupam Rasayan will become the new promoter of Bliss GVS Pharma, with the current promoters reclassified as public shareholders.

Why this matters

This development signifies a change in control and promoter status for Bliss GVS Pharma. The open offer provides an exit opportunity for public shareholders at a premium price. Anupam Rasayan has indicated intentions to support Bliss GVS Pharma's growth and may explore future operational restructuring.

The backstory

Bliss GVS Pharma reported total revenue of ₹1,000.64 crore and net income of ₹134.73 crore for the fiscal year ended March 31, 2026. This represents significant growth from ₹846.22 crore revenue and ₹90.26 crore net income in FY25. Anupam Rasayan, the acquirer, also saw substantial growth, with FY26 revenue at ₹2,383.63 crore and net income at ₹222.20 crore.

What changes now

Anupam Rasayan will assume promoter status, potentially leading to strategic realignments within Bliss GVS Pharma. Investors should expect the acquirer to drive the company's future growth and operational strategies.

Risks to watch

The transaction is contingent on fulfilling conditions precedent outlined in the SPA. Any failure to meet these conditions could lead to the withdrawal of the open offer, impacting shareholder expectations.

Peer comparison

Bliss GVS Pharma's FY26 revenue was ₹1,000.64 crore, with net income at ₹134.73 crore. Anupam Rasayan's FY26 revenue was ₹2,383.63 crore, with net income of ₹222.20 crore. Both companies demonstrated strong financial performance in the last fiscal year.

Context metrics (time-bound)

Bliss GVS Pharma's revenue grew 18.25% to ₹1,000.64 crore in FY26, while net income surged 49.27% to ₹134.73 crore.
Anupam Rasayan's revenue jumped 64.56% to ₹2,383.63 crore in FY26, with net income rising 38.90% to ₹222.20 crore.

What to track next

Investors should monitor the successful completion of the SPA conditions and the regulatory approvals for the open offer. The tendering period from July 16 to July 29, 2026, is critical for shareholders interested in participating in the offer.